XBIT - XBiotech Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

XBiotech Inc.

Building 4
Suite 100 8201 East Riverside Drive
Austin, TX 78744
United States
512-386-2900
http://www.xbiotech.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees59

Key Executives

NameTitlePayExercisedYear Born
Mr. John SimardFounder, Pres, CEO & Chairman786.97kN/A1962
Ms. Queena Han B.A., CPA, C.G.A.VP of Fin. & HR and Sec.198.95kN/A1967
Dr. Sushma ShivaswamyChief Scientific Officer312.48kN/A1978
Mr. Benjamín GuzmánSr. VP of Corp. Strategy & Fin.N/AN/A1956
Dr. William LevisInterim Medical Director and Member of Scientific Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection and influenza diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Corporate Governance

XBiotech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.